BACKGROUND/AIM: Data are limited regarding the use of pegfilgrastim in gynaecologic oncology. We evaluated its efficacy for maintaining dose intensity during chemotherapy. PATIENTS AND METHODS: We retrospectively examined the data of 65 women (26 pegfilgrastim users) who underwent primary surgical treatment for stages IB-IV endometrial cancer and had adjuvant chemotherapy containing platinum and taxane; the primary outcome was a relative dose intensity ≥85%. RESULTS: In the pegfilgrastim vs. the control group, body mass index (26.6±5.9 vs. 23.4±4.4), rate of relative dose intensity ≥85% (88.5% vs. 15.4%), plus other adverse event incidences were significantly higher; rate of neutropenia, total hospital visits during chemotherapy (11.0±2.1 vs. 18±5.6 days), unscheduled hospital visits (1.1±1.8 vs. 5.8±5.1 days), and unscheduled granulocyte colony-stimulating factor injections (0.58±1.7 vs. 6.4±5.1 days) were significantly lower. CONCLUSION: Pegfilgrastim can maintain a dose intensity of ≥85% during chemotherapy for the treatment of gynaecologic cancers and decrease hospital-visit frequency. Copyright
BACKGROUND/AIM: Data are limited regarding the use of pegfilgrastim in gynaecologic oncology. We evaluated its efficacy for maintaining dose intensity during chemotherapy. PATIENTS AND METHODS: We retrospectively examined the data of 65 women (26 pegfilgrastim users) who underwent primary surgical treatment for stages IB-IV endometrial cancer and had adjuvant chemotherapy containing platinum and taxane; the primary outcome was a relative dose intensity ≥85%. RESULTS: In the pegfilgrastim vs. the control group, body mass index (26.6±5.9 vs. 23.4±4.4), rate of relative dose intensity ≥85% (88.5% vs. 15.4%), plus other adverse event incidences were significantly higher; rate of neutropenia, total hospital visits during chemotherapy (11.0±2.1 vs. 18±5.6 days), unscheduled hospital visits (1.1±1.8 vs. 5.8±5.1 days), and unscheduled granulocyte colony-stimulating factor injections (0.58±1.7 vs. 6.4±5.1 days) were significantly lower. CONCLUSION: Pegfilgrastim can maintain a dose intensity of ≥85% during chemotherapy for the treatment of gynaecologic cancers and decrease hospital-visit frequency. Copyright
Authors: Rabbie K Hanna; Marek S Poniewierski; Robin A Laskey; Micael A Lopez; Aaron Shafer; Linda Van Le; Jeffrey Crawford; David C Dale; Paola A Gehrig; Angeles Alvarez Secord; Laura J Havrilesky; Gary H Lyman Journal: Gynecol Oncol Date: 2012-12-21 Impact factor: 5.482
Authors: Gery P Guy; K Robin Yabroff; Donatus U Ekwueme; Ashley Wilder Smith; Emily C Dowling; Ruth Rechis; Stephanie Nutt; Lisa C Richardson Journal: Health Aff (Millwood) Date: 2014-06 Impact factor: 6.301
Authors: Matti Aapro; Ralph Boccia; Robert Leonard; Carlos Camps; Mario Campone; Sylvain Choquet; Marco Danova; John Glaspy; Iwona Hus; Hartmut Link; Thamer Sliwa; Hans Tesch; Vicente Valero Journal: Support Care Cancer Date: 2017-08-25 Impact factor: 3.603
Authors: Gery P Guy; K Robin Yabroff; Donatus U Ekwueme; Katherine S Virgo; Xuesong Han; Matthew P Banegas; Anita Soni; Zhiyuan Zheng; Neetu Chawla; Ann M Geiger Journal: Am J Prev Med Date: 2015-12 Impact factor: 5.043
Authors: Donatus U Ekwueme; K Robin Yabroff; Gery P Guy; Matthew P Banegas; Janet S de Moor; Chunyu Li; Xuesong Han; Zhiyuan Zheng; Anita Soni; Amy Davidoff; Ruth Rechis; Katherine S Virgo Journal: MMWR Morb Mortal Wkly Rep Date: 2014-06-13 Impact factor: 17.586